News | May 09, 2010

CMS Raises SPECT, Cardiac CT Reimbursement

May 10, 2010 - The Centers for Medicare and Medicaid Services (CMS) just released a technical correction to the 2010 Medicare Physician Fee Schedule, which results in payment increases for myocardial perfusion imaging (MPI), cardiac computed tomography (CT), and cardiac catheterization codes.
These payments are retroactive to Jan. 1, 2010. The correction notice also includes a minor increase in the Medicare conversion factor from 36.066 to 36.0791, effective June through December 2010.

The corrections to MPI and CT codes address errors made in incorporating recommendations from the American Medical Association/Specialty Society Relative Value Scale Update Committee, or RUC, on direct practice expenses, such as medical supplies and equipment time, for these services. The errors included incorrect practice expense values for CPT codes 75571–75574 and 78451–78454. The corrected national average payment for 78452, single photon emission computed tomography (SPECT) MPI is $439, compared to the $379 published in the November final rule.

The American Society of Nuclear Cardiology (ASNC), the Society of Nuclear Medicine (SNM) and the American Medical Association (AMA) identified the errors in the SPECT codes. The Society of Cardiovascular Computed Tomography (SCCT) and the American College of Cardiology (ACC) worked with CMS to correct errors in the cardiac CT codes.

The correction notice also includes changes to malpractice relative value units (RVU) for cardiac catheterization services. In the final rule for the 2010 Medicare Physician Fee Schedule, CMS agreed with ACC, the Society for Cardiovascular Angiography and Interventions (SCAI), and the AMA that cardiac cath services should be assigned malpractice RVUs based on the higher surgical risk factor. However, the published RVUs and payment rates did not correctly reflect that policy change. With this notice, CMS has corrected its error.

The payment changes reflect the higher risk associated with invasive procedures. Therefore, there will be an increase from $235 to $253 for 93510-26, the professional component for left heart catheterization.

For more information: www.acc.org

Related Content

Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers
News | Lung Cancer | July 16, 2018
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
iSchemaView Brings RAPID Imaging Platform to Australia and New Zealand
News | Stroke | July 13, 2018
iSchemaView has signed Diagnostic Imaging Australia (DIA) to be the exclusive distributor for the RAPID cerebrovascular...
Zebra Medical Vision Announces FDA 510(k) Clearance of Coronary Calcium Algorithm
Technology | Computed Tomography (CT) | July 12, 2018
Zebra Medical Vision has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Coronary...
IAC Awards First CT Accreditation for a Mobile Stroke Unit
News | Computed Tomography (CT) | July 09, 2018
The Intersocietal Accreditation Commission (IAC) recently recognized the University of Tennessee Health Science Center...
HeartFlow Announces New Commercial Coverage With UnitedHealthcare
News | Computed Tomography (CT) | July 03, 2018
HeartFlow Inc. announced that UnitedHealthcare now covers the HeartFlow FFRct Analysis, extending access to their 45...
Peter Juodka, RT(CT) operates the 16-slice Siemens Somatom Scope CT scanner in the mobile stroke unit to assess stroke patients immediately at the call site.

Peter Juodka, RT(CT) operates the 16-slice Siemens Somatom Scope CT scanner in the mobile stroke unit to assess stroke patients immediately at the call site.

Feature | Computed Tomography (CT) | July 03, 2018 | By Jeff Zagoudis
Stroke is the fifth leading cause of death in the United States, responsible for more than 140,000 deaths in some of
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Overlay Init